Drug discovery, genomics, proteomics, bioinformatics

Dr. Klaus Fiebig was with OGI from 2006 - 2013. As CSO and VP of Research Programs, he oversaw OGI's research program portfolio and the team of program managers focused on this portfolio. He was also responsible for OGI's strategic approach to identifying, cultivating, and raising funds for genomics and proteomics projects and platforms in Ontario; and provided a point of contact for external stakeholders on these fronts.

Most recently Klaus has been Senior Director, Structural Biology and Computational Chemistry at Affinium Pharmaceuticals in Toronto. Among other duties, he was responsible for a 20 person strategic alliance with Pfizer focused on structural proteomics and structure-based drug discovery.

Prior to Affinium, Klaus was co-founder and CEO of a Frankfurt start-up, MRPharm, focused on NMR-based drug discovery and head of a similarly-focused academic team at the University of Frankfurt conducting collaborative drug discovery efforts with Aventis. Previously, he was a lead scientist with Xencor in Los Angeles responsible for improving their automatic computational protein design platform.

Klaus has a broad scientific background in the physical and biomedical fields. He received his PhD in Pharmaceutical Chemistry from the University of California at San Francisco and his undergraduate degrees in Physics from the Technical University Munich. Supported by fellowships from the Burroughs Wellcome Fund and the Howard Hughes Medical Institute, he completed postdoctoral research in protein folding at the University of Oxford and work in structural biology at Yale University. He has co-authored numerous scientific publications and holds several patents.